Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 13 November 2012 | By Alexander Gaffney, RAC,
Inspectors with the US Food and Drug Administration (FDA) have found microbial contamination, unevaluated adverse event reports, ongoing water leaks, contaminated hoods, multi-colored residues, insects and at least one bird in a compounding pharmacy owned by the same company now associated with a massive outbreak of fungal meningitis.
The observations-made in a FDA Form 483 inspection report of compounder Ameridose's Westborough, MA facility-closely track a 483 released on 28 October to the New England Compounding Center (NECC), whose products were found to have been contaminated with fungal meningitis.
That inspection found numerous instances of bacterial and fungal contamination, non-sterile autoclaves, vials visibly contaminated with "white, filamentous material" and air conditioning units routinely shut off at night.
The lapses at Ameridose appear to exceed those found at NECC. FDA's 20-page Form 483 details a cavalcade of violations indicating widespread failures of good manufacturing practices.
For instance, Ameridose's recording and reporting of adverse events frequently left out key communications from the official record and "contain[ed] vague, canned language to describe adverse events." FDA also said its observers found that Ameridose, "Failed to investigate microbial contamination observed at least 53 times during … sterility testing of sterile stock solutions intended to be used in the manufacture of sterile injectable drug products."
Added FDA: "It is noteworthy that when further testing was done, the testing often revealed additional non-sterile units."
A further litany of complaints was observed-a lack of potency testing, insufficient process validation, a lack of written procedures for key aspects of product testing-but the majority of FDA's deficiency observations were aimed at Ameridose's aseptic core.
Inspectors found:
In a statement, Ameridose said: "Ameridose's history shows clearly that we have not had any instance of contaminated products over the course of the past six years, which covers the manufacture and shipment of 70 million units of product. Ameridose is committed to addressing all observations in order to enhance our existing systems."
The company has already initiated a voluntary recall for all products manufactured at the facility and its facility remains closed.
Tags: Ameridose, NECC, Meningitis, Inspection Report, 483, Contamination, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.